Several kinases with inhibiting drugs available in the clinic for treatment of other cancer types or in clinical trials were suggested as upstream regulators for specific subtypes, for example, ErbB2 (MetA), AURORA A/B (MetB), and PDGF‐R‐beta (MetC; Table S4), hypothetically indicating possibilities for developing subtype‐related therapeutic strategies. This evidence concerns the gene ERBB2 and cancer.